Akbulak et al., 2017recently reported results of Holter ECG monitoring (HEM) following the first dose of fingolimod in a cohort of 64 MS patients. In this small cohort, the authors reported five (7.8%) patients with new-onset transient AV-block (AVB) (ranging from first-degree to second-degree type II (Mobitz)). In 4/5 patients (80%), the AVB could only be detected in the 72 h HEM with a median time of occurrence at 14 h. Although only one patient was symptomatic (dizziness), fingolimod treatment was discontinued in all of these mostly asymptomatic patients.
- Akbulak R.Ö.
- Rosenkranz S.C.
- Schaeffer B.N.
- Pinnschmidt H.O.
- Willems S.
- Heesen C.
- Hoffmann B.A.
Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
Mult. Scler. Relat. Disord. 2017; 19: 44-49https://doi.org/10.1016/j.msard.2017.10.020
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.Mult. Scler. Relat. Disord. 2017; 19: 44-49https://doi.org/10.1016/j.msard.2017.10.020
- Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.Am. Heart J. 2014; 168: 632-644https://doi.org/10.1016/j.ahj.2014.06.028
- Cardiac arrhythmias and atrioventricular block in a cohort of asymptomatic individuals without heart disease.Cardiology. 2007; 108: 111-116https://doi.org/10.1159/000095950
- First-dose effects of fingolimod: pooled safety data from three phase 3 studies.Mult. Scler. Relat. Disord. 2014; 3: 629-638https://doi.org/10.1016/j.msard.2014.05.005
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.J. Neurol. 2014; 261: 267-276https://doi.org/10.1007/s00415-013-7115-8
- Central autonomic dysfunction delays recovery of fingolimod induced heart rate slowing.PLoS One. 2015; 10: e0132139https://doi.org/10.1371/journal.pone.0132139
- Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects.Ther. Adv. Neurol. Disord. 2017; 10: 191-209https://doi.org/10.1177/1756285616682936
- Modulation of cardiac autonomic function by fingolimod initiation and predictors for fingolimod induced bradycardia in patients with multiple sclerosis.Front. Neurosci. 2017; 11: 540https://doi.org/10.3389/fnins.2017.00540
- Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study.BMC Neurol. 2017; 17: 11https://doi.org/10.1186/s12883-016-0789-7
- Cardiac safety profile of first dose of fingolimod for relapsing-remitting multiple sclerosis in real- world settings: data from a German prospective multi-center observational study.Neurol. Ther. 2016; : 1-9https://doi.org/10.1007/s40120-016-0051-7
- FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.J. Clin. Pharmacol. 2006; 46: 895-904https://doi.org/10.1177/0091270006289853
- Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Expert Opin. Pharmacother. 2017; 18: 1649-1660https://doi.org/10.1080/14656566.2017.1373093
- Multiple sclerosis in the real world: a systematic review of fingolimod as a case study.Autoimmun. Rev. 2017; 16: 1-22https://doi.org/10.1016/j.autrev.2017.02.007
- Trigonometric regressive spectral analysis: an innovative tool for evaluating the autonomic nervous system.J. Neural Transm. 2013; 120: S27-S33https://doi.org/10.1007/s00702-013-1054-5
Published online: March 19, 2018
Accepted: March 16, 2018
Received in revised form: March 8, 2018
Received: December 28, 2017
© 2018 Elsevier B.V. All rights reserved.